Literature DB >> 20298994

Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.

Jung-Sun Kim1, Jaedeok Kim, Donghoon Choi, Chan Joo Lee, Sang Hak Lee, Young-Guk Ko, Myeong-Ki Hong, Byoung-Keuk Kim, Seong Jin Oh, Dong Woon Jeon, Joo-Young Yang, Jung Rae Cho, Nam-Ho Lee, Yun-Hyeong Cho, Deok-Kyu Cho, Yangsoo Jang.   

Abstract

OBJECTIVES: This study sought to determine the efficacy of high-dose atorvastatin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
BACKGROUND: Previous randomized trials have demonstrated that statin pre-treatment reduced major adverse cardiac events (MACEs) in patients with stable angina pectoris and acute coronary syndrome. However, no randomized studies have been carried out with STEMI patients in a primary PCI setting.
METHODS: A total 171 patients with STEMI were randomized to 80-mg atorvastatin (n = 86) or 10-mg atorvastatin (n = 85) arms for pre-treatment before PCI. All patients were prescribed clopidogrel (600 mg) before PCI. After PCI, both groups were treated with atorvastatin (10 mg). The primary end point was 30-day incidence of MACE including death, nonfatal MI, and target vessel revascularization. Secondary end points included corrected thrombolysis in myocardial infarction frame count, myocardial blush grade, and ST-segment resolution at 90 min after PCI.
RESULTS: MACE occurred in 5 (5.8%) and 9 (10.6%) patients in the 80-mg and 10-mg atorvastatin pre-treatment arms, respectively (p = 0.26). Corrected thrombolysis in myocardial infarction frame count was lower in the 80-mg atorvastatin arm (26.9 +/- 12.3 vs. 34.1 +/- 19.0, p = 0.01). Myocardial blush grade and ST-segment resolution were also higher in the 80-mg atorvastatin arm (2.2 +/- 0.8 vs. 1.9 +/- 0.8, p = 0.02 and 61.8 +/- 26.2 vs. 50.6 +/- 25.8%, p = 0.01).
CONCLUSIONS: High-dose atorvastatin pre-treatment before PCI did not show a significant reduction of MACEs compared with low-dose atorvastatin but did show improved immediate coronary flow after primary PCI. High-dose atorvastatin may produce an optimal result for STEMI patients undergoing PCI by improving microvascular myocardial perfusion. (Efficacy of High-Dose AtorvaSTATIN Loading Before Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction [STATIN STEMI]; NCT00808717). Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20298994     DOI: 10.1016/j.jcin.2009.11.021

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  38 in total

Review 1.  Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of nine randomized controlled trials.

Authors:  Yangchun Liu; Qiang Su; Lang Li
Journal:  Clin Cardiol       Date:  2013-08-27       Impact factor: 2.882

2.  Early treatment with high-potency statins in patients with acute coronary syndrome-an example of personalized medicine.

Authors:  Emanuel Harari; Alon Eisen
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

3.  SECURE PCI: how important can a subgroup analysis be?

Authors:  Mathieu Kerneis; Megan K Yee; C Michael Gibson
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

4.  Timing of high intensity statin for acute coronary syndrome: how earlier initiation makes better?

Authors:  Choongki Kim; Donghoon Choi
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 5.  Remote conditioning the heart overview: translatability and mechanism.

Authors:  Michael Rahbek Schmidt; Andrew Redington; Hans Erik Bøtker
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

6.  No-reflow reversibility: a study based on serial assessment of multiple biomarkers.

Authors:  Giampaolo Niccoli; Francesco Fracassi; Nicola Cosentino; Elena Falcioni; Marco Roberto; Giuseppe De Luca; Antonio Maria Leone; Francesco Burzotta; Italo Porto; Carlo Trani; Anna Severino; Filippo Crea
Journal:  J Cardiovasc Transl Res       Date:  2013-09-06       Impact factor: 4.132

7.  Statins as first-line therapy for acute coronary syndrome?

Authors:  Petr Ostadal
Journal:  Exp Clin Cardiol       Date:  2012

Review 8.  Myocardial ischemia-reperfusion injury: a neglected therapeutic target.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

9.  Clinical and angiographic outcomes of wingspan stent placement for treatment of symptomatic intracranial stenosis: single center experience with 19 cases.

Authors:  Jun Hyoung Lee; Ji Kwang Yun; Dae Won Kim; Sung Don Kang
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2012-09-28

10.  A Novel Medical Treatment for Lipid Control in Patients with Unstable Angina Pectoris and Statin-Induced Liver Dysfunction.

Authors:  Fang Cui; Youliang Zhang; Qingmin Wei; Cuihua Liu; Junhui Wang; Meng Zhang
Journal:  Acta Cardiol Sin       Date:  2015-01       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.